TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL
Publication
, Conference
Carducci, M; Armstrong, A; Haggman, M; Stadler, WM; Gingrich, JR; Assikis, V; Forsberg, G; Olsson, A; Nordle, O; Pili, R
Published in: ANNALS OF ONCOLOGY
September 1, 2012
Duke Scholars
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
303 / 303
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Carducci, M., Armstrong, A., Haggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V., … Pili, R. (2012). TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL. In ANNALS OF ONCOLOGY (Vol. 23, pp. 303–303). Vienna, AUSTRIA: OXFORD UNIV PRESS.
Carducci, M., A. Armstrong, M. Haggman, W. M. Stadler, J. R. Gingrich, V. Assikis, G. Forsberg, A. Olsson, O. Nordle, and R. Pili. “TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL.” In ANNALS OF ONCOLOGY, 23:303–303. OXFORD UNIV PRESS, 2012.
Carducci M, Armstrong A, Haggman M, Stadler WM, Gingrich JR, Assikis V, et al. TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 303–303.
Carducci, M., et al. “TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL.” ANNALS OF ONCOLOGY, vol. 23, OXFORD UNIV PRESS, 2012, pp. 303–303.
Carducci M, Armstrong A, Haggman M, Stadler WM, Gingrich JR, Assikis V, Forsberg G, Olsson A, Nordle O, Pili R. TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 303–303.
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
303 / 303
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis